表紙
市場調査レポート

OTC医薬品および栄養補助食品:世界市場

Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets

発行 BCC Research 商品コード 295754
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
OTC医薬品および栄養補助食品:世界市場 Over-the-Counter (OTC) Drugs and Dietary Supplements: Global Markets
出版日: 2014年02月10日 ページ情報: 英文 150 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のOTC医薬品・栄養補助食品市場は、2012年に1,288億米ドルに達しました。同市場は2013年に1,427億米ドル、2018年には1,897億米ドルに達すると予測されており、その間のCAGRは5.9%を示す見込みです。

当レポートでは、世界のOTC医薬品・栄養補助食品市場について調査し、市場概要、世界市場の動向(実績データ・CAGR予測)、OTC医薬品市場における薬局の影響、最新のM&A活動アップデート、および主要企業のプロファイルなどを提供しており、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 処方薬から市販薬への再分類(RXからOTCへ)
  • OTC医薬品の一般的な投与方法
  • OTC医薬品の主要な治療分類

第4章 OTC医薬品・栄養補助食品の世界市場

  • 世界のOTC医薬品・栄養補助食品市場
  • 世界のOTC医薬品・栄養補助食品市場予測
  • OTC医薬品・栄養補助食品市場:地域別
  • 欧州のOTC医薬品市場
  • 英国のOTC医薬品市場
  • ドイツのOTC医薬品市場
  • フランスのOTC医薬品市場
  • アジア太平洋地域のOTC医薬品市場
  • ブラジル、ロシア、インドおよび中国(BRIC)のOTC医薬品市場
  • インドのOTC医薬品市場

第5章 世界のOTC医薬品・栄養補助食品売上:販売チャネル別

第6章 世界のOTC医薬品市場予測:治療別

  • 分類
  • 世界のOTC医薬品売上予測:治療分類別
  • 世界のOTC鎮痛薬/解熱剤市場予測
  • 世界のOTC抗ヒスタミン剤および咳・風邪薬市場予測
  • 世界のOTC胃腸薬市場予測
  • 世界のOTC皮膚用薬市場予測
  • 世界のOTCオーラルメディカルケア製品市場予測
  • 世界のOTCアイケア製品市場予測
  • 世界のOTC嫌煙製品市場予測
  • 世界のOTC栄養補助食品市場予測

第7章 OTC医薬品・栄養補助食品産業・市場

  • 分析
  • 概要
  • 定着市場
  • 定着途上市場
  • 非定着市場
  • OTC医薬品購入の実行
  • OTC医薬品における薬局の役割
  • OTC医薬品市場における規制の影響
  • 市場普及・拡大のための主な戦略的イニシアチブ
  • OTC医薬品産業の促進因子・障壁
  • OTC医薬品・栄養補助食品産業の強み、弱み、機会および脅威(SWOT)分析

第8章 企業プロファイル

図表リスト

目次
Product Code: PHM050B

The global market for OTC medicines and dietary supplements reached $128.8 billion in 2012. This market is expected to reach to $142.7 billion in 2013 and $189.7 billion in 2018, with a compound annual growth rate (CAGR) of 5.9%.

This report provides:

  • An overview of the global market for OTC drugs and dietary supplements.
  • Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
  • Information about how pharmacies affect the OTC drug market
  • Updates on the latest merger and acquistion activity
  • Company profiles of major players in the market

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report analyzes the global trends in OTC drugs and dietary supplements market. OTC medicines have been on the market since the 1970s; however, the late 19th and early 20th century witnessed certain changes and a positive approach globally that encouraged the business of OTC medicines and dietary supplements. The market for OTC medicines around the globe is witnessing new dynamics. This new segment of medicines has encouraged people toward self-care and self-medication on one hand, and on the other hand regulatory agencies are still in a dilemma in regard to the provision of medicines into the hands of people without supervision. The journey of self-medication was initiated as the treatment of common primary health conditions which is now transforming into wellness management. Consumers worldwide in both developed and developing nations are responding to self-care due to its many benefits. However, regulatory bodies, understanding that any medication comes with side effects, are cautious about encouraging self-medication practices. The permutations in drug approvals such as differentiating drugs as pharmacy only and general sales hesitance in approving point-of-sale other than pharmacies show that regulatory authorities are still in the process of finalizing regulatory policies for the OTC drugs. The objective of this study is to assess future prospects and opportunities in OTC drugs and dietary supplementsglobally. The report delves into questions such as: Which countries are establishing potential markets? Is the shift from prescription to nonprescription status still an effective strategy? What strategies current leaders in OTC drugs and dietary supplement manufacturers are adopting? How point of sales and channels of distribution drive sales of OTC drugs and dietary supplements? And what categories of OTC medicines will grow through 2018?

REASONS FOR DOING THE STUDY

Many nations are still in the process of developing strong regulatory policies for OTC drugs and define review process for reclassifying drugs from prescription to nonprescription status. These nations have yet to develop strong safety and quality standards and labeling policies for the OTC drugs. These developments will provide an opportunity to manufacturers and marketers of OTC medicines and dietary supplements to expand organically. The study will engender understanding as to the length and breadth of the market as well as encourage strategical thinking for entering into new potential markets, design marketing strategies and plan on the basis of improving regulatory approach of many nations.

SCOPE OF REPORT

The report covers developed and emerging markets in order to help readers understand:

  • The current state of the OTC medicines and dietary supplements market and the key markets for its future development.
  • New regulations that will influence the development of the OTC medicines and dietary supplements market.
  • Market drivers of and threats to the OTC medicines and dietary supplements industry.
  • Major regional trends in the global OTC medicines and dietary supplements market.
  • The competitive thrust of the market.

INTENDED AUDIENCE

  • Executives of pharmaceutical companies that are currently marketing OTC medicines and dietary supplements.
  • Executives of companies that provide third-party manufacturing and development facilities for OTC medicines and dietary supplements.
  • Manufacturers of bulk active ingredients and inactive ingredients such as base, resins, pigments and other raw materials for the manufacturing of OTC medicines and dietary supplements.
  • FMCG companies that intend to enter the OTC medicines and dietary supplements market.
  • Entrepreneurs, management consultants, and merger and acquisition (M&A) consultants.
  • Financial institutions, venture capitalists and angel investors.
  • Manufacturers and exporters of alternate OTC medicines and food supplements.
  • Government agencies, public health departments and organizations working in regulations and process development of OTC medicines and dietary supplements.

INFORMATION SOURCES

The information and analysis presented in this BCC Research report are based on firsthand information from primary executives, product managers and clinical specialists; background information obtained from various government, business, medical journal and trade magazines; and statistical data from various governmental organizations and trade associations.

Key information from published literature was used to conduct interviews with industry participants in order to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates as well as to formulate market projections. Data are expressed in 2012 U.S. dollars. The base year was 2012. Historical data are provided for 2011 and forecast data are provided for 2013 and 2018. Historical, base year and forecast data are provided for each market segment and sub-segment. Market shares are provided for each market segment for the base year of 2012.

ANALYST CREDENTIALS

Anand Gijare has proficiency in business research and consulting in the areas of industry trends, market expansion and business forecasting. Anand is a visionary with strategic thinking, analytical and problem-solving abilities. He is adept at anticipating questions and problems and providing answers and solutions.

Mr. Gijare has over 10 years' work experience with market research publishers, management consultants and government bodies. He has expertise on predictive and exploratory research projects for studying demand potential, market sizing, perceptions; analyzing macro and micro markets in terms of key gaps and opportunities. His expertise includes market trends and drivers, competitive scenarios, value chain analysis and in-depth global market forecast.

He has worked on research studies across variety of industrial sectors including pharmaceuticals, healthcare, information and communication technology.

Table of Contents

CHAPTER 1 INTRODUCTION 2

  • STUDY GOALS AND OBJECTIVES 2
  • REASONS FOR DOING THE STUDY 2
  • SCOPE OF REPORT 2
  • INTENDED AUDIENCE 3
  • INFORMATION SOURCES 3
  • ANALYST CREDENTIALS 4
  • RELATED BCC RESEARCH REPORTS 4
  • BCC RESEARCH ONLINE SERVICES 4
  • DISCLAIMER 4

CHAPTER 2 SUMMARY 6

  • SUMMARY TABLE GLOBAL MARKET FOR OTC MEDICINES AND DIETARY
  • SUPPLEMENTS THROUGH 2018 ($ MILLIONS) 6
  • SUMMARY FIGURE GLOBAL MARKET FOR OTC MEDICINES AND DIETARY
  • SUPPLEMENTS 2011-2018 ($ MILLIONS) 6
    • HIGHLIGHTS OF THE YEAR 2012 7
    • TRENDS IN OTC MEDICINES AND DIETARY SUPPLEMENTS THROUGH 2018 8
    • FORECAST TRENDS IN OTC MEDICINES BY THERAPEUTIC CLASS THROUGH 2018 9

CHAPTER 3 OVERVIEW 12

  • RECLASSIFYING PRESCRIPTION MEDICINES TO NONPRESCRIPTION (RX TO OTC) 13
  • COMMON ADMINISTRATION METHODS FOR OTC MEDICINES 14
    • TOPICAL ADMINISTRATION 14
      • Lotion 15
      • Cream 15
      • Ointment 15
      • Gel 16
      • Transdermal Patch 16
    • ORAL ADMINISTRATION 16
      • Tablets 16
      • Capsules 16
      • Medicinal Syrups 17
      • Medicated Chewing Gums 17
  • LEADING THERAPUTIC CLASSIFICATIONS OF OTC MEDICINES 17
    • ANALGESICS AND ANTIPYRATICS 17
      • Acetaminophen 17
      • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 18
      • TABLE 1 KEY OTC ANALGESICS AND ANTIPYRETICS BRANDS 18
    • ANTIHISTAMINES 19
    • TABLE 2 KEY OTC ANTIHISTAMINE BRANDS 19
    • COUGH AND COLD REMEDIES 19
      • Nasal Decongestants 20
      • Cough Remedies 20
    • TABLE 3 KEY OTC COUGH & COLD TREATMENT BRANDS 20
    • GASTROINTESTINAL DISORDER TREATMENTS 20
      • Antacids 21
      • TABLE 4 KEY OTC ANTACID BRANDS 21
      • H2 Blockers 21
      • TABLE 5 KEY OTC H2 BLOCKER BRANDS 22
      • Proton Pump Inhibitors (PPIs) 22
      • TABLE 6 KEY OTC PPIS BRANDS 22
      • SKINCARE AND DERMATOLOGICAL MEDICINES 23
      • Acne Treatments 23
      • TABLE 7 KEY OTC ACNE TREATMENT BRANDS 24
      • Psoriasis 24
      • TABLE 8 KEY OTC PSORIASIS TREATMENT BRANDS 24
    • EYE CARE PRODUCTS 25
      • Treatments for Dry Eye 25
      • TABLE 9 KEY OTC DRY EYE CARE BRANDS 25
      • Ocular Allergy Symptoms 25
      • TABLE 10 KEY OTC RED EYE TREATMENT BRANDS 25
      • Ocular/Eye Vitamins 26
      • TABLE 11 KEY OTC RED EYE TREATMENT BRANDS 26
      • Eyelid Hygiene 26
      • TABLE 12 KEY OTC RED EYE TREATMENT BRANDS 27
      • Contact Lenses Solution 27
      • TABLE 13 KEY OTC RED EYE TREATMENT BRANDS 27
    • ORAL MEDICAL CARE 27
      • Oral Debriding Agents and Wound Cleansers 27
      • Treatments for Dental Carries 28
      • Treatments on Gum Diseases 28
      • Treatments for Cold Sores 28
      • TABLE 14 KEY OTC ORAL MEDICAL CARE PRODUCTS 28
    • SMOKING CESSATION 29
      • Nicotine Gum 29
      • TABLE 15 NICOTINE GUM DOSAGE AND SCHEDULE 30
      • Additonal Notes Regarding Nicotine Gum: 30
      • TABLE 16 KEY BRANDS AND MARKETERS OF NICOTINE GUMS 31
      • Nicotine Lozenges 31
      • TABLE 17 NICOTINE LOZENGE DOSAGE AND SCHEDULE 31
      • Additonal Notes Regarding Nicotine Lozenges: 32
      • TABLE 18 KEY BRANDS AND MARKETERS OF NICOTINE LOZENGES 32
      • Nicotine Patch 32
      • TABLE 19 NICOTINE PATCH DOSAGES AND SCHEDULE 33
      • Additonal Notes Regarding Nicotine Patches: 33
      • TABLE 20 KEY BRANDS AND MARKETERS OF NICOTINE PATCHES 34
    • DIETARY SUPPLEMENTS (VMS) 34
      • Eating Disorders 35
      • Treatments for Vitamins and Mineral Deficiency 35
      • Vitamins and Mineral Supplements (VMS) 35
      • Regulations for Dietary Supplements 35
      • TABLE 21 KEY DIETARY SUPPLEMENT BRANDS 37

CHAPTER 4 GLOBAL MARKETS FOR OTC MEDICINES AND DIETARY SUPPLEMENTS 39

  • GLOBAL OTC MEDICINE AND DIETARY SUPPLEMENT MARKET - 2012 39
  • TABLE 22 GLOBAL OTC MEDICINES AND DIETARY SUPPLEMENT MARKET BY
  • SEGMENT, THROUGH 2018 ($ MILLIONS) 39
  • TABLE 23 ESTABLISHING MARKETS' PERFORMANCE, 2012 ($ MILLIONS/%) 40
  • TABLE 24 LOW PERFORMERS OF YEAR 2012 ($ MILLIONS) 40
  • TABLE 25 EMERGING MARKETS OF YEAR 2012 ($ MILLIONS) 40
  • GLOBAL MARKET FOR OTC MEDICINES AND DIETARY SUPPLEMENTS, 2013 TO
  • 2018 42
  • TABLE 26 GLOBAL OTC MEDICINE AND DIETARY SUPPLEMENT MARKET THROUGH
  • 2018 ($ MILLIONS) 42
    • GLOBAL MARKET REVIEW 42
      • U.S. Market 42
      • European Market 42
      • Asia-Pacific Market 42
      • BRIC Market 43
      • TABLE 27 CHANGE IN MARKET SHARE OF OTC MEDICINES & DIETARY
      • SUPPLEMENTS BY MARKET 2012 AND 2018 (%) 43
  • MARKETS FOR OTC MEDICINES AND DIETARY SUPPLEMENTS BY REGION - 2013 TO 2018 44
    • THE U.S. OTC MEDICINES MARKET 2013 TO 2018 44
    • REGULATIONS AND APPROVAL PROCESS: THE U.S. 45
      • Medicines Developed Under the OTC Drug Monograph Process 45
        • OTC Drug Review 45
          • OTC Monograph 46
      • OTC Medicines Developed Through the NDA Process 46
      • Updated List of Prescription to Over-the-Counter (OTC) Switches 47
      • TABLE 28 UPDATED LIST OF RX-TO-OTC SWITCH IN THE U.S. FROM 2001 TO 2013 47
    • THE U.S. NONPRESCRIPTION SAFE-USE REGULATORY EXPANSION (NSURE)
    • INITIATIVE 48
    • THE U.S. OTC MEDICINE MARKET 2013 THROUGH 2018 49
    • TABLE 29 GLOBAL MARKET FORECAST FOR THE U.S. BY CATEGORY THROUGH
    • 2018 ($ MILLIONS) 50
    • TABLE 30 CHANGE IN SHARE OF THE U.S. MARKET BY MARKET SECTOR, 2012 AND
    • 2018 (%) 51
  • EUROPE'S OTC MEDICINES MARKET 51
    • REGULATIONS AND APPROVAL PROCESS IN EUROPE 52
      • National Procedure 52
      • Decentralized Procedure 52
      • Mutual Recognition Procedure 53
      • Centralized Procedure 53
    • SMART REGULATION 2015-EUROPE AS A SINGLE MARKET 53
    • EUROPE'S OTC MEDICINE MARKET 2013 THROUGH 2018 54
    • TABLE 31 GLOBAL MARKET FORECAST FOR EUROPE THROUGH 2018 ($ MILLIONS) 55
    • TABLE 32 GLOBAL MARKET FORECAST FOR EUROPE BY CATEGORY THROUGH 2018
    • ($ MILLIONS) 55
    • TABLE 33 CHANGE IN MARKET SHARE OF EUROPEAN MARKET BY CATEGORY 2012
    • AND 2018 (%) 56
  • THE U.K. OTC MEDICINES MARKET 2013 THROUGH 2018 57
    • REGULATIONS AND APPROVAL PROCESS IN THE U.K. 57
      • Better Regulation of Over-the-Counter Medicines Initiative (BROMI)
      • U.K. 59
    • POM TO P AND P TO GSL RECLASSIFICATIONS TO JUNE 2013 59
    • TABLE 34 UPDATED LIST OF PERSCRIPTION ONLY MEDICINES TO PHARMACY AND
    • PHARMACY TO GENERAL SALE LIST RECLASSIFICATIONS - U.K. ([YEAR] TO JUNE
    • 2013)
    • 59
    • RECLASSIFICATIONS IN THE U.K. APPROVED SINCE JUNE 2012 62
    • TABLE 35 RECENT RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING
    • AUTHORIZATIONS - U.K. 62
    • U.K. OTC MARKET 2013 THROUGH 2018 62
    • TABLE 36 GLOBAL MARKET FORECAST FOR THE U.K. BY CATEGORY THROUGH
    • 2018 ($ MILLIONS) 63
    • TABLE 37 CHANGE IN MARKET SHARE OF THE U.K. MARKET BY CATEGORY 2012
    • AND 2018 (%) 63
  • GERMANY'S OTC MEDICINES MARKET 2013 THROUGH 2018 64
    • REGULATIONS AND APPROVAL PROCESS IN GERMANY 64
    • GERMAN OTC MARKET 2013 THROUGH 2018 65
    • TABLE 38 GLOBAL MARKET FORECAST FOR GERMANY BY CATEGORY, THROUGH
    • 2018 ($ MILLIONS) 66
    • TABLE 39 CHANGE IN MARKET SHARE FOR GERMANY BY CATEGORY THROUGH
    • 2018 (%) 67
  • FRANCE'S OTC MEDICINES MARKET 2013 THROUGH 2018 67
    • TABLE 40 GLOBAL MARKET FORECAST FOR FRANCE BY CATEGORY THROUGH 2018
    • ($ MILLIONS) 68
    • TABLE 41 CHANGE IN MARKET SHARE OF FRANCE BY CATEGORY THROUGH 2018
    • (%) 68
    • POLAND'S OTC MEDICINES MARKET 2013 THROUGH 2018 69
    • TABLE 42 GLOBAL MARKET FORECAST FOR POLAND BY CATEGORY THROUGH
    • 2018 ($ MILLIONS) 69
    • TABLE 43 CHANGE IN MARKET SHARE OF POLAND BY CATEGORY 2012 AND 2018
    • (%) 70
  • ASIA-PACIFIC OTC MEDICINES MARKET 2013 THROUGH 2018 70
    • TABLE 44 GLOBAL MARKET FORECAST FOR ASIA-PACIFIC BY CATEGORY THROUGH
    • 2018 ($ MILLIONS) 71
    • TABLE 45 CHANGE IN MARKET SHARE OF ASIA-PACIFIC BY CATEGORY, 2012 AND
    • 2018 (%) 71
    • JAPAN'S OTC MEDICINES MARKET 72
      • Regulations and Approval Process - Japan 72
        • Developments in 2013 73
      • First Kind Pharmaceutical Newly Approved - Japan's OTC
      • Pharmaceutical Sales System 73
    • TABLE 46 UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN
    • JAPAN - NOV. 2007 TO MAY 2013 73
      • Japan's OTC MEDICINES MARKET 2013 through 2018 76
    • TABLE 47 GLOBAL MARKET FORECAST FOR JAPAN BY CATEGORY THROUGH 2018
    • ($ MILLIONS) 77
    • TABLE 48 CHANGE IN MARKET SHARE OF ASIA-PACIFIC BY CATEGORY 2011 AND
    • 2018 (%) 77
    • AUSTRALIA AND NEW ZEALAND'S OTC MEDICINES MARKET 2013
    • THROUGH 2018 78
    • Regulations and Approval Process - Australia 78
    • NEW ZEALAND 79
    • JOINT AUSTRALIAN AND NEW ZEALAND PHASED IMPLEMENTATION PLAN
    • 2013 80
      • N2 Applications (Using OTC Monographs) Version1, September 2013 80
      • Level N3, N4 and N5 Applications 81
    • AUSTRALIA AND NEW ZEALAND - OTC MEDICINES MARKET 2013 THROUGH
    • 2018 81
    • TABLE 49 GLOBAL MARKET FORECAST FOR AUSTRALIA AND NEW ZEALAND BY
    • CATEGORY, THROUGH 2018 ($ MILLIONS) 81
    • TABLE 50 CHANGE IN MARKET SHARE OF AUSTRALIA/NEW ZEALAND 2012 AND
    • 2018 (%) 82
  • BRAZIL, RUSSIA, INDIA AND CHINA (BRIC) - OTC MEDICINES MARKET 2013
    • THROUGH 2018 82
    • TABLE 51 GLOBAL MARKET FORECAST FOR BRIC BY CATEGORY THROUGH 2018 ($
    • MILLIONS) 83
    • SPURRING LATENT NEED 83
    • BRIC OTC MEDICINES MARKET 2013 THROUGH 2018 84
    • TABLE 52 CHANGE IN MARKET SHARE OF BRIC COUNTRIES BY CATEGORY 2012
    • AND 2018 (%) 84
    • BRAZIL - OTC MEDICINES MARKET 85
    • BRAZIL - OTC MEDICINES MARKET 2013 THROUGH 2018 85
    • TABLE 53 GLOBAL MARKET FORECAST FOR BRAZIL BY CATEGORY THROUGH 2018
    • ($ MILLIONS) 85
    • TABLE 54 CHANGE IN MARKET SHARE OF BRAZIL BY CATEGORY, 2012 AND 2018
    • (%) 86
    • RUSSIA - OTC MEDICINES MARKET 86
    • RUSSIA - OTC MEDICINES MARKET 2013 THROUGH 2018 87
    • TABLE 55 GLOBAL MARKET FORECAST FOR RUSSIA BY CATEGORY THROUGH 2018
    • ($ MILLIONS) 87
    • TABLE 56 CHANGE IN MARKET SHARE OF RUSSIA BY CATEGORY, 2012 AND 2018
    • (%) 88
    • CHINA - OTC MEDICINES MARKET 88
    • REGULATIONS AND APPROVAL PROCESS - CHINA 88
    • CHINA - OTC MEDICINES MARKET 2013 THROUGH 2018 89
    • TABLE 57 GLOBAL MARKET FORECAST FOR CHINA BY CATEGORY THROUGH 2018
    • ($ MILLIONS) 90
    • TABLE 58 CHANGE IN MARKET SHARE OF CHINA BY CATEGORY, 2012 AND 2018 (%) 90
  • INDIA - OTC MEDICINES MARKET 91
    • INDIA - REGULATIONS AND APPROVAL PROCESSES 91
    • INDIA - OTC MEDICINES MARKET 2013 THROUGH 2018 92
    • TABLE 59 GLOBAL MARKET FORECAST FOR INDIA BY CATEGORY THROUGH 2018 ($
    • MILLIONS) 92
    • TABLE 60 CHANGE IN MARKET SHARE OF INDIA BY CATEGORY, 2012 AND 2018 (%) 93

CHAPTER 5 GLOBAL SALES OF OTC MEDICINES AND DIETARY SUPPLEMENTS BY

  • SALES CHANNELS 95
  • GLOBAL MARKET FORECAST FOR OTC MEDICINES AND DIETARY SUPPLEMENTS
  • BY SALES CHANNELS, THROUGH 2018 96
  • TABLE 61 GLOBAL MARKET FOR OTC MEDICINES AND DIETARY SUPPLEMENTS BY
  • SALES CHANNELS, THROUGH 2018 ($ MILLIONS) 96
  • TABLE 62 CHANGE IN MARKET SHARE BY SALES CHANNELS, 2012 AND 2018 (%) 96

CHAPTER 6 GLOBAL MARKET FORECAST FOR OTC MEDICINES BY THERUPEUTIC

  • CLASSIFICATION 98
  • GLOBAL SALES FORECAST BY THERUPEUTIC CLASSIFICATION FOR OTC
  • MEDICINES 98
  • TABLE 63 GLOBAL SALES FOR OTC MEDICINES BY REGION, THROUGH 2018 ($
  • MILLIONS) 98
  • TABLE 64 CHANGE IN MARKET SHARE OF OTC MEDICINES BY COUNTRY, 2012 AND
  • 2018 (%) 99
  • TABLE 65 GLOBAL MARKET FOR OTC MEDICINES BY THERUPEUTIC CLASSIFICATION,
  • THROUGH 2018 ($ MILLIONS) 99
  • TABLE 66 CHANGE IN MARKET SHARE OF OTC MEDICINES BY THERUPEUTIC
  • CLASSIFICATION, 2012 AND 2018 (%) 100
  • GLOBAL MARKET FORECAST FOR OTC ANALGESICS/ANTIPYRETICS 2013
  • THROUGH 2018 100
  • Analgesics and Antipyretics OTC Market 2013 through 2018 101
  • TABLE 67 GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS,
  • THROUGH 2018 ($ MILLIONS) 101
  • TABLE 68 CHANGE IN MARKET SHARE OF OTC ANALGESICS AND ANTIPYRETIC,
  • 2012 AND 2018 (%) 102
  • GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND
  • COLD MEDICINES 2013 THROUGH 2018 102
  • TABLE 69 GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND
  • COLD THROUGH 2018 ($ MILLIONS) 103
  • TABLE 70 CHANGE IN MARKET SHARE OF OTC ANTIHISTAMINE AND COUGH AND
  • COLD, 2012 AND 2018 (%) 103
  • GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS
  • 2013 THROUGH 2018 104
  • TABLE 71 GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS,
  • THROUGH 2018 ($ MILLIONS) 104
  • TABLE 72 CHANGE IN MARKET SHARE OF OTC GASTROINTESTINAL PRODUCTS,
  • 2012 AND 2018 (%) 105
  • GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL MEDICINES 2013
  • THROUGH 2018 105
  • TABLE 73 GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL MEDICINES,
  • THROUGH 2018 ($ MILLIONS) 105
  • TABLE 74 CHANGE IN MARKET SHARE OF OTC DERMATOLOGICAL MEDICINES,
  • THROUGH 2018 (%) 106
  • GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS
  • 2013 THROUGH 2018 106
  • TABLE 75 GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS
  • THROUGH 2018 ($ MILLIONS) 107
  • TABLE 76 CHANGE IN MARKET SHARE OF OTC ORAL MEDICAL CARE PRODUCTS,
  • 2012 AND 2018 (%) 107
  • GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS 2013
  • THROUGH 2018 108
  • TABLE 77 GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH
  • 2018 ($ MILLIONS) 108
  • TABLE 78 CHANGE IN MARKET SHARE OF OTC EYE CARE PRODUCTS, 2012 AND
  • 2018 (%) 108
  • GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS
  • 2013 THROUGH 2018 109
    • High Rate of Smokers Quitting in Developed Countries 109
    • Decrease in Smoking Rates at Saturation Point in Developed Markets 109
    • Smoking Rates are Increasing in Developing Markets 110
    • Strategic Initiatives to Increase Smoking Cessation in Developing
    • Countries 110
    • Developing and Poor Countries Sign WHO FCTC Treaty 110
    • WHO FCTC Progress Report 2012 111
    • TABLE 79 ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN
    • 2012 WHO FCTC PROGRESS REPORT (%) 111
    • TABLE 80 ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO
    • FCTC PROGRESS REPORT (%) 111
    • TABLE 81 ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO
    • FCTC PROGRESS REPORT (%) 112
    • FIGURE 1 GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS
    • REPORT (%) 112
    • TABLE 82 GLOBAL IMPLEMETATION OF FCTC ARTICLES: 2012 REPORT 114
    • Implementation of Article 14 in 2012 116
    • TABLE 83 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC 117
    • Political and Legal Interventions Influence Markets 118
    • TABLE 84 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012 (%) 119
    • Socioeconomic Factors of Smoking 120
    • TABLE 85 PROJECTED GLOBAL CAUSE OF DEATH BY DISEASE (%) 121
    • TABLE 86 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES ($
    • BILLIONS) 122
    • Technological Developments Concerning Smoking 122
    • FIGURE 2 ONGOING STUDIES, BY REGION (NO. OF STUDIES) 122
    • TABLE 87 GLOBAL SIZE OF SMOKING CESSATION MEDICINE MARKET BY REGION,
    • THROUGH 2018 ($ MILLIONS) 124
    • TABLE 88 GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS
    • BY REGION THROUGH 2018 ($ MILLIONS) 124
    • TABLE 89 CHANGE IN MARKET SHARE OF OTC SMOKING CESSATION PRODUCTS
    • THROUGH 2018 (%) 125
  • GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENTS (VMS) 2013
  • THROUGH 2018 125
  • TABLE 90 GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS
  • BY REGION, THROUGH 2018 ($ MILLIONS) 126
  • TABLE 91 CHANGE IN MARKET SHARE OF DIETARY SUPPLEMENTS BY REGION,
  • 2012 AND 2018 (%) 126

CHAPTER 7 OTC MEDICINES AND DIETARY SUPPLEMENT INDUSTRY AND MARKET

  • ANALYSIS 129
  • OVERVIEW 129
  • ESTABLISHED MARKETS 129
  • ESTABLISHING MARKETS 130
  • NON-ESTABLISHED MARKETS 131
  • THE PRACTICE OF BUYING OTC MEDICINES 131
  • ROLE OF PHARMACY IN OTC MEDICINES 131
  • REGULATORY INFLUENCE ON OTC MEDICINE MARKET 132
  • KEY STRATEGIC INITIATIVES FOR MARKET PENETRATION AND EXPANSION 132
    • ACQUISITION OF MARKETING AUTHORIZATION - KEY MARKET
    • PENETRATION AND EXPANSION STRATEGY 132
    • EXPANSIONS, PARTNERSHIPS AND JOINT VENTURES 133
    • THIRD-PARTY CONTRACTING 134
  • DRIVERS AND BARRIERS OF OTC MEDICINE INDUSTRY 134
    • THE RECENT DRIVERS FOR THE OTC MEDICINES AND DIETARY
    • SUPPLEMENT MARKET 134
  • STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS (SWOT) ANALYSIS
  • OF THE OTC MEDICINE AND DIETARY SUPPLEMENT INDUSTRY 135
  • TABLE 92 SWOT ANALYSIS OF OTC MEDICINE AND DIETARY SUPPLEMENT
  • INDUSTRY 136

CHAPTER 8 COMPANY PROFILES 138

  • ALACER CORP. 138
  • ALCON INC. 138
  • ALFRESA PHARMA CORPORATION 138
  • ALKALON A/S 138
  • ALLIANCE BOOTS 139
  • ALLIANCE HEALTHCARE 139
  • ALLIANCE HEALTHCARE DEUTSCHLAND 139
  • ALLIANCE HEALTHCARE FRANCE 139
  • ALLERGAN, INC. 140
  • ALTICOR 140
  • NUTRILITE 140
  • ARKOPHARMA PHARMACEUTICAL LABORATORIES (LABORATOIRES
  • PHARMACEUTIQUES) 140
  • ASPEN HOLDINGS 141
  • ASPEN PHARMACARE AUSTRALIA PTY. LTD. 141
  • BAUSCH & LOMB 141
  • BAYER HEALTHCARE AG 141
  • BOEHRINGER INGELHEIM GMBH 142
  • CARMA LABORATORIES, INC. 142
  • CHATTEM INC. 142
  • CILAG AG 143
  • COLGATE-PALMOLIVE COMPANY 143
  • CORDIA HEALTHCARE (CAVENDISH PHARMACEUTICALS) 143
  • DAIICHI SANKYO CO., LTD. 144
  • DERMA SCIENCES 144
  • EYESCIENCE LABS 144
  • FERTIN PHARMA A/S 145
  • GABA INTERNATIONAL AG 145
  • GALDERMA S.A. 145
  • GEMINI PHARMACEUTICALS, INC. 145
  • GENOMMA LAB INTERNATIONAL 146
  • GLAXOSMITHKLINE PLC 146
  • HISAMITSU PHARMACEUTICAL CO., INC. 147
  • INSIGHT PHARMACEUTICALS LLC 147
  • JOHNSON & JOHNSON 147
  • KOWA COMPANY, LTD. 148
  • LAKE CONSUMER PRODUCTS, INC. 148
  • MANX HEALTHCARE LIMITED 148
  • MCM KLOSTERFRAU VERTRIEBS GMBH (KLOSTERFRAU HEALTHCARE GROUP) 149
  • MCNEIL CONSUMER HEALTHCARE 149
  • MEDA AB 149
  • MELALEUCA, INC. 149
  • MERCK CORPORATE HEADQUARTERS 150
  • MERZ PHARMA 150
  • MOCHIDA PHARMACEUTICAL CO., LTD. 150
  • NEPENTES SA / NEPENTES PHARMA SP. Z O.O. 151
  • NEUTROGENA CORP. 151
  • NORTHEAST PHARMACEUTICAL GROUP CO. LTD 151
  • NOVARTIS INTERNATIONAL AG 151
  • NOW FOODS 152
  • PERRIGO CO. 152
  • PFIZER INC. 152
  • PGT HEALTHCARE (DIVISION OF PROCTER & GAMBLE) 152
  • PHARMAVITE LLC 153
  • PIERRE FABRE PHARMACEUTICALS INC. 153
  • PIRAMAL HEALTHCARE LTD 153
  • PRESTIGE BRANDS HOLDINGS, INC. 154
  • RECKITT BENCKISER PLC. 154
  • RECKITT BENCKISER (NORTH AMERICA) INC. 154
  • RECORDATI PHARMA GMBH 154
  • REVOLYMER (U.K.) LTD 155
  • SAGE PRODUCTS LLC 155
  • SANOFI 155
  • SATO PHARMACEUTICAL CO., LTD. 156
  • SHAKLEE CORPORATION 156
  • SHAKLEE CHINA-CORPORATE OFFICE 156
  • STADA ARZNEIMITTEL AG 156
  • SWISSE WELLNESS PTY LTD. 157
  • TAISHO PHARMACEUTICAL HOLDINGS 157
  • TAKEDA PHARMACEUTICALS LTD. 157
  • TISSO NATURPRODUKTE GMBH 158
  • WELLSPRING PHARMACEUTICAL CORPORATION 158
  • ZEAVISION, LLC 158

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR OTC MEDICINES AND DIETARY
  • SUPPLEMENTS THROUGH 2018 ($ MILLIONS) 6
  • TABLE 1 KEY OTC ANALGESICS AND ANTIPYRETICS BRANDS 18
  • TABLE 2 KEY OTC ANTIHISTAMINE BRANDS 19
  • TABLE 3 KEY OTC COUGH & COLD TREATMENT BRANDS 20
  • TABLE 4 KEY OTC ANTACID BRANDS 21
  • TABLE 5 KEY OTC H2 BLOCKER BRANDS 22
  • TABLE 6 KEY OTC PPIS BRANDS 22
  • TABLE 7 KEY OTC ACNE TREATMENT BRANDS 24
  • TABLE 8 KEY OTC PSORIASIS TREATMENT BRANDS 24
  • TABLE 9 KEY OTC DRY EYE CARE BRANDS 25
  • TABLE 10 KEY OTC RED EYE TREATMENT BRANDS 25
  • TABLE 11 KEY OTC RED EYE TREATMENT BRANDS 26
  • TABLE 12 KEY OTC RED EYE TREATMENT BRANDS 27
  • TABLE 13 KEY OTC RED EYE TREATMENT BRANDS 27
  • TABLE 14 KEY OTC ORAL MEDICAL CARE PRODUCTS 28
  • TABLE 15 NICOTINE GUM DOSAGE AND SCHEDULE 30
  • TABLE 16 KEY BRANDS AND MARKETERS OF NICOTINE GUMS 31
  • TABLE 17 NICOTINE LOZENGE DOSAGE AND SCHEDULE 31
  • TABLE 18 KEY BRANDS AND MARKETERS OF NICOTINE LOZENGES 32
  • TABLE 19 NICOTINE PATCH DOSAGES AND SCHEDULE 33
  • TABLE 20 KEY BRANDS AND MARKETERS OF NICOTINE PATCHES 34
  • TABLE 21 KEY DIETARY SUPPLEMENT BRANDS 37
  • TABLE 22 GLOBAL OTC MEDICINES AND DIETARY SUPPLEMENT MARKET BY
  • SEGMENT, THROUGH 2018 ($ MILLIONS) 39
  • TABLE 23 ESTABLISHING MARKETS' PERFORMANCE, 2012 ($ MILLIONS/%) 40
  • TABLE 24 LOW PERFORMERS OF YEAR 2012 ($ MILLIONS) 40
  • TABLE 25 EMERGING MARKETS OF YEAR 2012 ($ MILLIONS) 40
  • TABLE 26 GLOBAL OTC MEDICINE AND DIETARY SUPPLEMENT MARKET THROUGH
  • 2018 ($ MILLIONS) 42
  • TABLE 27 CHANGE IN MARKET SHARE OF OTC MEDICINES & DIETARY SUPPLEMENTS
  • BY MARKET 2012 AND 2018 (%) 43
  • TABLE 28 UPDATED LIST OF RX-TO-OTC SWITCH IN THE U.S. FROM 2001 TO 2013 47
  • TABLE 29 GLOBAL MARKET FORECAST FOR THE U.S. BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 50
  • TABLE 30 CHANGE IN SHARE OF THE U.S. MARKET BY MARKET SECTOR, 2012 AND
  • 2018 (%) 51
  • TABLE 31 GLOBAL MARKET FORECAST FOR EUROPE THROUGH 2018 ($ MILLIONS) 55
  • TABLE 32 GLOBAL MARKET FORECAST FOR EUROPE BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 55
  • TABLE 33 CHANGE IN MARKET SHARE OF EUROPEAN MARKET BY CATEGORY 2012
  • AND 2018 (%) 56
  • TABLE 34 UPDATED LIST OF PERSCRIPTION ONLY MEDICINES TO PHARMACY AND
  • PHARMACY TO GENERAL SALE LIST RECLASSIFICATIONS - U.K. ([YEAR] TO JUNE
  • 2013)
  • 59
  • TABLE 35 RECENT RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING
  • AUTHORIZATIONS - U.K. 62
  • TABLE 36 GLOBAL MARKET FORECAST FOR THE U.K. BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 63
  • TABLE 37 CHANGE IN MARKET SHARE OF THE U.K. MARKET BY CATEGORY 2012
  • AND 2018 (%) 63
  • TABLE 38 GLOBAL MARKET FORECAST FOR GERMANY BY CATEGORY, THROUGH
  • 2018 ($ MILLIONS) 66
  • TABLE 39 CHANGE IN MARKET SHARE FOR GERMANY BY CATEGORY THROUGH 2018
  • (%) 67
  • TABLE 40 GLOBAL MARKET FORECAST FOR FRANCE BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 68
  • TABLE 41 CHANGE IN MARKET SHARE OF FRANCE BY CATEGORY THROUGH 2018 (%) 68
  • TABLE 42 GLOBAL MARKET FORECAST FOR POLAND BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 69
  • TABLE 43 CHANGE IN MARKET SHARE OF POLAND BY CATEGORY 2012 AND 2018 (%) 70
  • TABLE 44 GLOBAL MARKET FORECAST FOR ASIA-PACIFIC BY CATEGORY THROUGH
  • 2018 ($ MILLIONS) 71
  • TABLE 45 CHANGE IN MARKET SHARE OF ASIA-PACIFIC BY CATEGORY, 2012 AND
  • 2018 (%) 71
  • TABLE 46 UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN JAPAN
  • - NOV. 2007 TO MAY 2013 73
  • TABLE 47 GLOBAL MARKET FORECAST FOR JAPAN BY CATEGORY THROUGH 2018 ($
  • MILLIONS) 77
  • TABLE 48 CHANGE IN MARKET SHARE OF ASIA-PACIFIC BY CATEGORY 2011 AND
  • 2018 (%) 77
  • TABLE 49 GLOBAL MARKET FORECAST FOR AUSTRALIA AND NEW ZEALAND BY
  • CATEGORY, THROUGH 2018 ($ MILLIONS) 81
  • TABLE 50 CHANGE IN MARKET SHARE OF AUSTRALIA/NEW ZEALAND 2012 AND
  • 2018 (%) 82
  • TABLE 51 GLOBAL MARKET FORECAST FOR BRIC BY CATEGORY THROUGH 2018 ($
  • MILLIONS) 83
  • TABLE 52 CHANGE IN MARKET SHARE OF BRIC COUNTRIES BY CATEGORY 2012 AND
  • 2018 (%) 84
  • TABLE 53 GLOBAL MARKET FORECAST FOR BRAZIL BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 85
  • TABLE 54 CHANGE IN MARKET SHARE OF BRAZIL BY CATEGORY, 2012 AND 2018 (%) 86
  • TABLE 55 GLOBAL MARKET FORECAST FOR RUSSIA BY CATEGORY THROUGH 2018
  • ($ MILLIONS) 87
  • TABLE 56 CHANGE IN MARKET SHARE OF RUSSIA BY CATEGORY, 2012 AND 2018 (%) 88
  • TABLE 57 GLOBAL MARKET FORECAST FOR CHINA BY CATEGORY THROUGH 2018 ($
  • MILLIONS) 90
  • TABLE 58 CHANGE IN MARKET SHARE OF CHINA BY CATEGORY, 2012 AND 2018 (%) 90
  • TABLE 59 GLOBAL MARKET FORECAST FOR INDIA BY CATEGORY THROUGH 2018 ($
  • MILLIONS) 92
  • TABLE 60 CHANGE IN MARKET SHARE OF INDIA BY CATEGORY, 2012 AND 2018 (%) 93
  • TABLE 61 GLOBAL MARKET FOR OTC MEDICINES AND DIETARY SUPPLEMENTS BY
  • SALES CHANNELS, THROUGH 2018 ($ MILLIONS) 96
  • TABLE 62 CHANGE IN MARKET SHARE BY SALES CHANNELS, 2012 AND 2018 (%) 96
  • TABLE 63 GLOBAL SALES FOR OTC MEDICINES BY REGION, THROUGH 2018 ($
  • MILLIONS) 98
  • TABLE 64 CHANGE IN MARKET SHARE OF OTC MEDICINES BY COUNTRY, 2012 AND
  • 2018 (%) 99
  • TABLE 65 GLOBAL MARKET FOR OTC MEDICINES BY THERUPEUTIC CLASSIFICATION,
  • THROUGH 2018 ($ MILLIONS) 99
  • TABLE 66 CHANGE IN MARKET SHARE OF OTC MEDICINES BY THERUPEUTIC
  • CLASSIFICATION, 2012 AND 2018 (%) 100
  • TABLE 67 GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS,
  • THROUGH 2018 ($ MILLIONS) 101
  • TABLE 68 CHANGE IN MARKET SHARE OF OTC ANALGESICS AND ANTIPYRETIC, 2012
  • AND 2018 (%) 102
  • TABLE 69 GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND
  • COLD THROUGH 2018 ($ MILLIONS) 103
  • TABLE 70 CHANGE IN MARKET SHARE OF OTC ANTIHISTAMINE AND COUGH AND
  • COLD, 2012 AND 2018 (%) 103
  • TABLE 71 GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS,
  • THROUGH 2018 ($ MILLIONS) 104
  • TABLE 72 CHANGE IN MARKET SHARE OF OTC GASTROINTESTINAL PRODUCTS, 2012
  • AND 2018 (%) 105
  • TABLE 73 GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL MEDICINES,
  • THROUGH 2018 ($ MILLIONS) 105
  • TABLE 74 CHANGE IN MARKET SHARE OF OTC DERMATOLOGICAL MEDICINES,
  • THROUGH 2018 (%) 106
  • TABLE 75 GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS
  • THROUGH 2018 ($ MILLIONS) 107
  • TABLE 76 CHANGE IN MARKET SHARE OF OTC ORAL MEDICAL CARE PRODUCTS,
  • 2012 AND 2018 (%) 107
  • TABLE 77 GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH
  • 2018 ($ MILLIONS) 108
  • TABLE 78 CHANGE IN MARKET SHARE OF OTC EYE CARE PRODUCTS, 2012 AND
  • 2018 (%) 108
  • TABLE 79 ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN 2012
  • WHO FCTC PROGRESS REPORT (%) 111
  • TABLE 80 ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO
  • FCTC PROGRESS REPORT (%) 111
  • TABLE 81 ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC
  • PROGRESS REPORT (%) 112
  • TABLE 82 GLOBAL IMPLEMETATION OF FCTC ARTICLES: 2012 REPORT 114
  • TABLE 83 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC 117
  • TABLE 84 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012 (%) 119
  • TABLE 85 PROJECTED GLOBAL CAUSE OF DEATH BY DISEASE (%) 121
  • TABLE 86 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES ($
  • BILLIONS) 122
  • TABLE 87 GLOBAL SIZE OF SMOKING CESSATION MEDICINE MARKET BY REGION,
  • THROUGH 2018 ($ MILLIONS) 124
  • TABLE 88 GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS
  • BY REGION THROUGH 2018 ($ MILLIONS) 124
  • TABLE 89 CHANGE IN MARKET SHARE OF OTC SMOKING CESSATION PRODUCTS
  • THROUGH 2018 (%) 125
  • TABLE 90 GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS
  • BY REGION, THROUGH 2018 ($ MILLIONS) 126
  • TABLE 91 CHANGE IN MARKET SHARE OF DIETARY SUPPLEMENTS BY REGION, 2012
  • AND 2018 (%) 126
  • TABLE 92 SWOT ANALYSIS OF OTC MEDICINE AND DIETARY SUPPLEMENT INDUSTRY 136

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR OTC MEDICINES AND DIETARY
  • SUPPLEMENTS 2011-2018 ($ MILLIONS) 6
  • FIGURE 1 GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS
  • REPORT (%) 112
  • FIGURE 2 ONGOING STUDIES, BY REGION (NO. OF STUDIES) 122
Back to Top